Petr Burkon1,2, Iveta Selingerova3, Marek Slavik1,2, Petr Pospisil1,2, Lukas Bobek1, Libor Kominek1, Pavel Osmera4, Tomas Prochazka1,2, Miroslav Vrzal1, Tomas Kazda1,2,5, Pavel Slampa1,2. 1. Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia. 2. Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czechia. 3. Research Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czechia. 4. Department of Nuclear Medicine and PET Center, Masaryk Memorial Cancer Institute, Brno, Czechia. 5. Central European Institute of Technology, Masaryk University, Brno, Czechia.
Abstract
AIMS: To evaluate the efficacy and toxicity of extracranial stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic lymph node involvement in the mediastinum, retroperitoneum, or pelvis, in a consecutive group of patients from real clinical practice outside clinical trials. METHODS: A retrospective analysis of 90 patients with a maximum of four oligometastases and various primary tumors (the most common being colorectal cancers). The endpoints were local control of treated metastases (LC), freedom from widespread dissemination (FFWD), progression-free survival (PFS), overall survival (OS), and freedom from systemic treatment (FFST). Acute and delayed toxicities were also evaluated. RESULTS: The median follow-up after SBRT was 34.9 months. The LC rate at three and five years was 68.4 and 56.3%, respectively. The observed median FFWD was 14.6 months, with a five-year FFWD rate of 33.7%. The median PFS was 9.4 months; the three-year PFS rate was 19.8%. The median FFST was 14.0 months; the five-year FFST rate was 23.5%. The OS rate at three and five years was 61.8 and 39.3%, respectively. Median OS was 53.1 months. The initial dissemination significantly shortened the time to relapse, death, or activation of systemic treatment-LC (HR 4.8, p < 0.001), FFWD (HR 2.8, p = 0.001), PFS (HR 2.1, p = 0.011), FFST (HR 2.4, p = 0.005), OS (HR 2.2, p = 0.034). Patients classified as having radioresistant tumors noticed significantly higher risk in terms of LC (HR 13.8, p = 0.010), FFWD (HR 3.1, p = 0.006), PFS (HR 3.5, p < 0.001), FFST (HR 3.2, p = 0.003). The multivariable analysis detected statistically significantly worse survival outcomes for initially disseminated patients as well as separately in groups divided according to radiosensitivity. No grade III or IV toxicity was reported. CONCLUSION: Our study shows that targeted SBRT is a very effective and low toxic treatment for oligometastatic lymph node involvement. It can delay the indication of cytotoxic chemotherapy and thus improve and maintain patient quality of life. The aim of further studies should focus on identifying patients who benefit most from SBRT, as well as the correct timing and dosage of SBRT in treatment strategy.
AIMS: To evaluate the efficacy and toxicity of extracranial stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic lymph node involvement in the mediastinum, retroperitoneum, or pelvis, in a consecutive group of patients from real clinical practice outside clinical trials. METHODS: A retrospective analysis of 90 patients with a maximum of four oligometastases and various primary tumors (the most common being colorectal cancers). The endpoints were local control of treated metastases (LC), freedom from widespread dissemination (FFWD), progression-free survival (PFS), overall survival (OS), and freedom from systemic treatment (FFST). Acute and delayed toxicities were also evaluated. RESULTS: The median follow-up after SBRT was 34.9 months. The LC rate at three and five years was 68.4 and 56.3%, respectively. The observed median FFWD was 14.6 months, with a five-year FFWD rate of 33.7%. The median PFS was 9.4 months; the three-year PFS rate was 19.8%. The median FFST was 14.0 months; the five-year FFST rate was 23.5%. The OS rate at three and five years was 61.8 and 39.3%, respectively. Median OS was 53.1 months. The initial dissemination significantly shortened the time to relapse, death, or activation of systemic treatment-LC (HR 4.8, p < 0.001), FFWD (HR 2.8, p = 0.001), PFS (HR 2.1, p = 0.011), FFST (HR 2.4, p = 0.005), OS (HR 2.2, p = 0.034). Patients classified as having radioresistant tumors noticed significantly higher risk in terms of LC (HR 13.8, p = 0.010), FFWD (HR 3.1, p = 0.006), PFS (HR 3.5, p < 0.001), FFST (HR 3.2, p = 0.003). The multivariable analysis detected statistically significantly worse survival outcomes for initially disseminated patients as well as separately in groups divided according to radiosensitivity. No grade III or IV toxicity was reported. CONCLUSION: Our study shows that targeted SBRT is a very effective and low toxic treatment for oligometastatic lymph node involvement. It can delay the indication of cytotoxic chemotherapy and thus improve and maintain patient quality of life. The aim of further studies should focus on identifying patients who benefit most from SBRT, as well as the correct timing and dosage of SBRT in treatment strategy.
Authors: P Burkon; T Kazda; P Pospisil; M Slavik; L Kominek; I Selingerova; D M Blakaj; T Prochazka; M Vrzal; Z Rehak; P Slampa Journal: Neoplasma Date: 2018-11-23 Impact factor: 2.575
Authors: Anita M Werensteijn-Honingh; Petra S Kroon; Dennis Winkel; Ellart M Aalbers; Bram van Asselen; Gijsbert H Bol; Kevin J Brown; Wietse S C Eppinga; Corine A van Es; Markus Glitzner; Eline N de Groot-van Breugel; Sara L Hackett; Martijn Intven; Jan G M Kok; Charis Kontaxis; Alexis N Kotte; Jan J W Lagendijk; Mariëlle E P Philippens; Rob H N Tijssen; Jochem W H Wolthaus; Simon J Woodings; Bas W Raaymakers; Ina M Jürgenliemk-Schulz Journal: Radiother Oncol Date: 2019-02-01 Impact factor: 6.280
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Daniel E Spratt; Whitney H Beeler; Fabio Y de Moraes; Laurence D Rhines; Joseph J Gemmete; Neeraj Chaudhary; David B Shultz; Sean R Smith; Alejandro Berlin; Max Dahele; Ben J Slotman; Kelly C Younge; Mark Bilsky; Paul Park; Nicholas J Szerlip Journal: Lancet Oncol Date: 2017-12 Impact factor: 41.316
Authors: David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Roel Schlijper; Glenn S Bauman; Joanna Laba; X Melody Qu; Andrew Warner; Suresh Senan Journal: J Clin Oncol Date: 2020-06-02 Impact factor: 44.544
Authors: Tugce Kutuk; Robert Herrera; Teuta Z Mustafayev; Gorkem Gungor; Gamze Ugurluer; Banu Atalar; Rupesh Kotecha; Matthew D Hall; Muni Rubens; Kathryn E Mittauer; Jessika A Contreras; James McCulloch; Noah S Kalman; Diane Alvarez; Tino Romaguera; Alonso N Gutierrez; Jacklyn Garcia; Adeel Kaiser; Minesh P Mehta; Enis Ozyar; Michael D Chuong Journal: Adv Radiat Oncol Date: 2022-04-25